Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial

Research output: Contribution to journalArticlepeer-review

Authors

  • Lia Gore
  • Maria Lucia de Martino Lee
  • Carmino Antonio De Souza
  • Yves Bertrand
  • Nobuko Hijiya
  • Linda C. Stork
  • Nack-Gyun Chung
  • Rocio Cardenas Cardos
  • Tapan Saikia
  • Franca Fagioli
  • Jong Jin Seo
  • Judith Landman-Parker
  • Donna L. Lancaster
  • Andrew E. Place
  • Karen R. Rabin
  • Mariana Sacchi
  • Rene Swanink
  • C. Michel Zwaan

Colleges, School and Institutes

Abstract

Purpose: Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome–positive (Ph+) leukemias.

Methods: CA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients < 18 years of age receiving dasatinib. There are three cohorts: (1) imatinib-resistant/intolerant CML-CP, (2) imatinib-resistant/intolerant CML in accelerated/blast phase or Ph+ acute lymphoblastic leukemia (n = 17), and (3) newly diagnosed CML-CP treated with tablets or powder for oral suspension. Major cytogenetic response > 30% for imatinib-resistant/intolerant patients and complete cytogenetic response (CCyR) > 55% for newly diagnosed patients were of clinical interest.

Results: Of 113 patients with CML-CP, 14 (48%) who were imatinib-resistant/intolerant and 61 (73%) who were newly diagnosed remained on treatment at time of analysis. Major cytogenetic response > 30% was reached by 3 months in the imatinib-resistant/intolerant group and CCyR > 55% was reached by 6 months in the newly diagnosed CML-CP group. CCyR and major molecular response by 12 months, respectively, were 76% and 41% in the imatinib-resistant/intolerant group and 92% and 52% in newly diagnosed CML-CP group. Progression-free survival by 48 months was 78% and 93% in the imatinib-resistant/intolerant and newly diagnosed CML-CP groups, respectively. No dasatinib-related pleural or pericardial effusion, pulmonary edema, or pulmonary arterial hypertension were reported. Bone growth and development events were reported in 4% of patients.

Conclusion: In the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is a safe, effective treatment of pediatric CML-CP. Target responses to first- or second-line dasatinib were met early, and deep molecular responses were observed. Safety of dasatinib in pediatric patients was similar to that observed in adults; however, no cases of pleural or pericardial effusion or pulmonary arterial hypertension were reported.

Details

Original languageEnglish
Pages (from-to)1330-1338
Number of pages9
JournalJournal of Clinical Oncology
Volume36
Issue number13
Early online date2 Mar 2018
Publication statusPublished - 1 May 2018